Cancer Research and Treatment

Original Articles

Understanding the Unmet Needs in Diagnostics and Therapeutics of Chronic Lymphocytic Leukemia in Korea: Eun Sang Yu, Soyean Kwon, Seonggyu Byeon, Ja Min Byun, Sung-Soo Park, Ki-Seong Eom, Chul Won Choi; Received September 15, 2025 Accepted January 23, 2026 Published online January 26, 2026; DOI: https://doi.org/10.4143/crt.2025.1008 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
Since the U.S. Food and Drug Administration approval of ibrutinib in 2012, the treatment landscape for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has undergone a paradigm shift. Nevertheless, the disease remains incurable, posing ongoing clinical challenges. In Korea, these challenges are further compounded by unique characteristics of patients and national healthcare system.
Materials and Methods
The multicenter retrospective analysis included 519 patients diagnosed with CLL/SLL between 2006 and 2024 across three major Korean institutions.
Results
The median age at diagnosis was 62 years. Among 267 patients who received first-line therapy, 68.9% (184/267) were treated with immunochemotherapy, 19.4% (52/267) with cytotoxic chemotherapy, and 11.2% (30/267) with a Bruton tyrosine kinase (BTK) inhibitor. Since the Korean approval of ibrutinib in 2016, BTK inhibitor use has steadily increased. Subgroup analyses demonstrated that patients receiving BTK inhibitor–based therapy had more favorable outcomes compared to those treated with immunochemotherapy.
Conclusion
This study provides the most comprehensive real-world reflection of current diagnostic and therapeutic practices in Korea. Through comparative analysis with international data, it offers valuable insights into the limitations of current CLL/SLL care and may inform future strategies to optimize management in the Korean context.

1,204 View
57 Download

Prognostic Factors for Relapse and the Role of Maintenance Therapy in Acute Promyelocytic Leukemia: A Real-World Multicenter Study in Korea: Kunye Kwak, Mihee Kim, Dongjin Shin, Changgon Kim, Yoon Seok Choi, Ka-Won Kang, Byung Soo Kim, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Chul Won Choi, Byung-Hyun Lee, Se Ryeon Lee, Hwa Jung Sung, Chang-Hoon Lee, Seo-Yeon Ahn, Ho-Young Yhim, Jae-Sook Ahn, Yong Park; Received August 26, 2025 Accepted November 6, 2025 Published online November 10, 2025; DOI: https://doi.org/10.4143/crt.2025.929 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub

Purpose
Acute promyelocytic leukemia (APL) is curable, but relapse remains a concern, particularly in patients treated with all-trans retinoic acid (ATRA) and chemotherapy-based regimens. The identification of prognostic factors for relapse is important for enhanced survival outcomes.
Materials and Methods
This retrospective multicenter study analyzed the clinical outcomes and prognostic factors for relapse in 286 Korean patients treated with ATRA and idarubicin-based chemotherapy protocols between 2002 and 2024.
Results
Propensity score-matched analysis revealed key prognostic factors, such as post-consolidation measurable residual disease (MRD) (hazard ratio [HR], 20.16, p < 0.001) and male sex (HR, 5.96; p=0.016). No significant benefit of ATRA-based maintenance therapy was observed in relapse-free survival, compared with observation alone. We also found that FLT3–internal tandem duplication mutations were associated with an increased risk of relapse.
Conclusion
These findings highlight prognostic factors for relapse and the importance of individualized therapeutic strategies for high-risk patients. Moreover, our findings indicate that post-consolidation MRD is the most significant predictor of relapse, emphasizing the need for molecular profiling and longitudinal monitoring. Future prospective studies should validate these prognostic markers and refine personalized therapeutic approaches for APL.

Citations

Citations to this article as recorded by

Induction-phase blood arsenic concentration and relapse risk in pediatric acute promyelocytic leukemia treated with arsenic and all-trans retinoic acid
Qingyuan Xu, Linya Wang, Ning Liao, Mincui Zheng, Yunpeng Dai, Diying Shen, Shaoyan Hu, Li Wang, Qun Hu, Xin Tian, Xiaohuan Wang, Yuanyuan Zhang, Pengli Huang, Jiaole Yu, Ying Wu, Wei Lin, Peijing Qi, Jia Fan, Ruidong Zhang, Yaguang Peng, Huyong Zheng, Hu
Leukemia.2026; 40(10): 2342. CrossRef

1,830 View
109 Download
1 Crossref

Hematologic malignancy

Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera: Ji Yun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Sang Kyun Sohn, Seug Yun Yoon, Soo-Mee Bang, Gyeong-Won Lee, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Young Hoon Park, Sung-Eun Lee; Cancer Res Treat. 2026;58(3):954-962. Published online June 26, 2025; DOI: https://doi.org/10.4143/crt.2025.552

Abstract PDF Supplementary Material PubReader ePub

Purpose
Conventional management of low-risk polycythemia vera (PV), consisting of phlebotomy and aspirin, often fails to adequately control symptoms and hematologic parameters. This study evaluated the efficacy and safety of ropeginterferon alfa-2b (Ropeg) in low-risk PV patients requiring cytoreductive therapy.
Materials and Methods
In this sub-analysis of an open-label, multicenter trial, 42 patients received Ropeg for 48 weeks. The primary endpoint was a reduction in phlebotomy frequency, while secondary endpoints included complete hematologic response (CHR), changes in JAK2V617F allele burden, and safety.
Results
Among 42 patients, Ropeg significantly reduced mean phlebotomy frequency per year from 3.0 to 0.5 (p < 0.05) and improved CHR rates (69.1% at 48 weeks). The JAK2V617F allele burden decreased, and hydroxyurea-naïve patients showed better responses. The most frequently reported treatment-related adverse events included elevated liver enzymes and alopecia. Most adverse events were mild or moderate, with no grade 4 or 5 events reported.
Conclusion
These findings suggest that Ropeg is a promising treatment option for low-risk PV by effectively reducing the need for phlebotomy and demonstrating efficacy and safety.

Citations

Citations to this article as recorded by

Two Decades of Real-World Data Reveals: Vigilance Signals of Drug-Induced Gingival Bleeding
Bozhao Wang, Xiaodong Chen, Deli Niu, Yuru Wang, Yuanyuan Zhang, Jian Li
International Dental Journal.2026; 76(2): 109409. CrossRef
Modern and multidisciplinary care in polycythemia vera
Francesca Palandri, Chiara Sartor, Alessandro Pileri, Olga Addimanda, Christian Gagliardi, Michelangelo Sartori, Monica Benni, Maddalena Giannella, Federica Lo Dato, Elena Sabattini, Lorenzo Fiorino, Alessandra Dedola, Filippo Branzanti, Maria B. Rondinel
Annals of Hematology.2026;[Epub] CrossRef
Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera
Anthony Michael Hunter, Albert Qin, Lucia Masarova, Ghaith Abu-Zeinah, Sung-Eun Lee, Ji Yun Lee, Jie Jin, Zhang Lei, Keita Kirito, Kazuya Shimoda, Toshiaki Sato, Daoxiang Wu, Yun Lee, Han Chiu, Abdulraheem Yacoub, Norio Komatsu, Ruben Mesa
Leukemia & Lymphoma.2026; : 1. CrossRef
Complete Hematological Response Coupled with Molecular Response in Polycythemia Vera Treatment with Ropeginterferon Alfa-2b
Veronica Vecchio, Rossella Cacciola, Emma Cacciola
Life.2026; 16(8): 1220. CrossRef

4,839 View
286 Download
3 Web of Science
4 Crossref

Long-term Psychiatric and Endocrine Complications Following Hematopoietic Stem Cell Transplantation in Hematologic Disease in Korea: A Nation-Wide Cohort Study: Min Ji Jeon, Eunjin Noh, Seok Joo Moon, Eun Sang Yu, Chul Won Choi, Dae Sik Kim, Eun Joo Kang; Cancer Res Treat. 2024;56(4):1262-1269. Published online May 9, 2024; DOI: https://doi.org/10.4143/crt.2024.047

Abstract PDF PubReader ePub

Purpose
Numerous patients experience long-term complications after hematopoietic stem cell transplantation (HSCT). This study aimed to identify the frequency and risk factors for psychiatric and endocrine complications following HSCT through big data analyses.
Materials and Methods
We established a cohort of patients with hematologic disease who underwent HSCT in Korea between 2010 and 2012 using the Health Insurance Review & Assessment Service data. A total of 3,636 patients were identified, and insurance claims were tracked using psychiatric and endocrine diagnostic International Classification of Diseases, 10th Revision codes for the ensuing decade. We identified the incidence rates of long-term complications based on the baseline disease and HSCT type. Prognostic factors for each complication were scrutinized using logistic regression analysis.
Results
A total of 1,879 patients underwent allogeneic HSCT and 1,757 patients received autologous HSCT. Post-HSCT, 506 patients were diagnosed with depression, 465 with anxiety disorders, and 659 with diabetes. The highest incidence of long-term complications occurred within the first year post-HSCT (12.2%), subsequently decreasing over time. Risk factors for depressive disorders after allogeneic HSCT included female sex, a total body irradiation–based conditioning regimen, and cyclosporine. Identified risk factors for diabetes mellitus comprised old age, total body irradiation–based conditioning regimen, and non-antithymocyte globulin protocol. Regarding autologous HSCT, only female sex was identified as a risk factor for depressive disorders, whereas elderly patients and those with multiple myeloma were identified as poor prognostic factors for diabetes mellitus.
Conclusion
The incidence of long-term psychiatric and endocrine complications post-HSCT remains high, and patients with risk factors for these complications require vigilant follow-up.

Citations

Citations to this article as recorded by

Psychological Prehabilitation for People Undergoing Autologous Stem Cell Transplant: A Qualitative Study
K. Wilkin, F. Lynch, J. Todd, V. White
Psycho-Oncology.2026;[Epub] CrossRef
The feasibility of ovarian tissue cryopreservation in selected females after hematopoietic stem cell transplantation
Jiaojiao Cheng, Juan Du, Muqing Gu, Xiangyan Ruan, Fengyu Jin, Jing Jin, Zecheng Wang, Yurui Wu, Qin Zhou, Yanqiu Li, Yanglu Li, Lingling Jiang, Mingzhen Zhang, Anming Liu, Yuejiao Wang, Alfred O. Mueck
Bone Marrow Transplantation.2026; 61(8): 1063. CrossRef
Hematopoietic stem cell transplantation-associated partial lipodystrophy
Masanori Adachi
Clinical Pediatric Endocrinology.2026; 35(3): 201. CrossRef

4,869 View
108 Download
4 Web of Science
3 Crossref

Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study: Yu Ri Kim, Jin Seok Kim, Won Seog Kim, Hyeon Seok Eom, Deok-Hwan Yang, Sung Hwa Bae, Hyo Jung Kim, Jae Hoon Lee, Suk-Joong Oh, Sung-Soo Yoon, Jae-Yong Kwak, Chul Won Choi, Min Kyoung Kim, Sung Young Oh, Hye Jin Kang, Seung Hyun Nam, Hyeok Shim, Joon Seong Park, Yeung-Chul Mun, Cheolwon Suh, the Korean Society of Hematology Lymphoma Working Party; Cancer Res Treat. 2023;55(4):1355-1362. Published online March 30, 2023; DOI: https://doi.org/10.4143/crt.2023.271

Abstract PDF Supplementary Material PubReader ePub

Purpose
This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL).
Materials and Methods
Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R-CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy.
Results
Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent grade 3 adverse events (40.0%) and 5 treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016).
Conclusion
Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients. ClinicalTrials.gov ID: NCT01054781.

Citations

Citations to this article as recorded by

Design, Conduct, and Analysis of Externally Controlled Trials
Jiali Liu, Minghong Yao, Mingqi Wang, Wan Jie, Yanmei Liu, Xiaochao Luo, Jiayidaer Huan, Kelin Deng, Ke Deng, Kang Zou, Ying Zhang, Ling Li, Xin Sun
JAMA Network Open.2025; 8(9): e2530277. CrossRef

8,513 View
283 Download
1 Web of Science
1 Crossref

Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects: Chul Won Choi, Min Ho Jeong, You-Soo Park, Cheol-Hun Son, Hong-Rae Lee, Eun-Kyoung Koh; Cancer Res Treat. 2019;51(2):464-473. Published online June 6, 2018; DOI: https://doi.org/10.4143/crt.2018.186

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the efficacy of stereotactic body radiation therapy (SBRT) as a tumor-associated antigen (TAA) presentation method for dendritic cell (DC) sensitization and evaluate its effect in combination with immunotherapy using an intratumoral injection of immature DCs (iDCs).
Methods
and Materials CT-26 colon carcinoma cell was used as a cancer cell line. Annexin V staining and phagocytosis assays were performed to determine the appropriate radiation dose and incubation time to generate TAAs. BALB/c mice were used for in vivo experiments. Cancer cells were injected into the right legs and left flanks to generate primary and metastatic tumors, respectively. The mice were subjected to radiation therapy (RT) alone, intradermal injection of electroporated DCs alone, or RT in combination with iDC intratumoral injection (RT/iDC). Tumor growth measurement and survival rate analysis were performed. Enzyme-linked immunospot and cytotoxicity assays were performed to observe the effect of different treatments on the immune system.
Results
Annexin V staining and phagocytosis assays showed that 15 Gy radiation dose and 48 hours of incubation was appropriate for subsequent experiments. Maximum DC sensitization and T-cell stimulation was observed with RT as compared to other TAA preparation methods. In vivo assays revealed statistically significant delay in the growth of both primary and metastatic tumors in the RT/iDC group. The overall survival rate was the highest in the RT/iDC group.
Conclusion
The combination of SBRT and iDC vaccination may enhance treatment effects. Clinical trials and further studies are warranted in the future.

Citations

Citations to this article as recorded by

Amplifying tumour antigen presentations from intratumourally entrapped dendritic cells
Jingjing Zhang, Jiaxin Du, Kuoran Xing, Xianyue Ji, Kefeng Pu, Mao Wang, Zhiyang Li, Xianguang Ding, David Tai Leong, Lianhui Wang
Nature Nanotechnology.2026; 21(7): 1048. CrossRef
Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology
Augustin Suffisseau, Johanne Seguin, Katia Lemdani, Sarah Diakhaby, Claude Capron, Mostafa El Hajjam, Fabrice Ruiz, Frederique Peschaud, Nathalie Mignet, Robert Malafosse
Current Oncology Reports.2026;[Epub] CrossRef
Gamma Knife stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: a phase II trial analysis
Yiran Zhang, Hanyang Guan, Shijin Liu, Haoquan Li, Zili Bian, Jiashuai He, Zhan Zhao, Shenghui Qiu, Tianmu Mo, Xiangwei Zhang, Zuyang Chen, Hui Ding, Xiaoxu Zhao, Liang Wang, Yunlong Pan, Jinghua Pan
eLife.2025;[Epub] CrossRef
Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
Yanhong Shi, Xiaoyan Ma, Dan He, Bingwei Dong, Tianyun Qiao
Frontiers in Immunology.2023;[Epub] CrossRef
Therapeutic strategies for gastric cancer targeting immune cells: Future directions
Yan Zhao, Yuansong Bai, Meili Shen, Yapeng Li
Frontiers in Immunology.2022;[Epub] CrossRef
Recent Advances and Future Perspective of DC-Based Therapy in NSCLC
Iris A. E. van der Hoorn, Georgina Flórez-Grau, Michel M. van den Heuvel, I. Jolanda M. de Vries, Berber Piet
Frontiers in Immunology.2021;[Epub] CrossRef
Successful Treatment of Advanced Gastric Cancer with Brain Metastases through an Abscopal Effect by Radiation and Immune Checkpoint Inhibitor Therapy
Momotaro Muto, Hirotaka Nakata, Kenichi Ishigaki, Shion Tachibana, Moe Yoshida, Mizue Muto, Nobuyuki Yanagawa, Toshikatsu Okumura
Journal of Gastric Cancer.2021; 21(3): 319. CrossRef
Intelligent photothermal dendritic cells restart the cancer immunity cycle through enhanced immunogenic cell death
Zhihong Sun, Guanjun Deng, Xinghua Peng, Xiuli Xu, Lanlan Liu, Jiaofeng Peng, Yifan Ma, Pengfei Zhang, Austin Wen, Yifan Wang, Zhaogang Yang, Ping Gong, Wen Jiang, Lintao Cai
Biomaterials.2021; 279: 121228. CrossRef
Prediction and identification of novel HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from endocan
Gaohai Shao, Qingjun Liu, Ling Yang, Guibo Feng, Wang Zhao, Zhongyan Huang, Zhao Yang
Journal of Inflammation.2020;[Epub] CrossRef
HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity

Yin Liao, Shuya Liu, Shaozhi Fu, Jingbo Wu
OncoTargets and Therapy.2020; Volume 13: 6859. CrossRef
Immunotherapy as sensitizer for local radiotherapy
Ben G.L. Vanneste, Evert J Van Limbergen, Ludwig Dubois, Iryna V. Samarska, L. Wieten, M. J.B. Aarts, T. Marcelissen, Dirk De Ruysscher
OncoImmunology.2020;[Epub] CrossRef
Effective Combinations of Radiotherapy and Immunotherapy in the Treatment of Esophageal Squamous Cell Carcinoma
Yang Yang, Hong Ge
Future Oncology.2020; 16(31): 2537. CrossRef
Abscopal effect of stereotactic radiotherapy combined with anti‐PD‐1/PD‐L1 immunotherapy: Mechanisms, clinical efficacy, and issues
Hongqing Zhuang
Cancer Communications.2020; 40(12): 649. CrossRef
A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
Siddhartha Srivastava, Christina Jackson, Timothy Kim, John Choi, Michael Lim
Cancers.2019; 11(4): 537. CrossRef
Current status of immune checkpoint inhibition in early-stage NSCLC
J. Vansteenkiste, E. Wauters, B. Reymen, C.J. Ackermann, S. Peters, D. De Ruysscher
Annals of Oncology.2019; 30(8): 1244. CrossRef
Local Irradiation Sensitized Tumors to Adoptive T Cell Therapy via Enhancing the Cross-Priming, Homing, and Cytotoxicity of Antigen-Specific CD8 T Cells
Jin-Zhi Lai, Yan-Yang Zhu, Mei Ruan, Ling Chen, Qiu-Yu Zhang
Frontiers in Immunology.2019;[Epub] CrossRef
Nutraceutical Compounds as Sensitizers for Cancer Treatment in Radiation Therapy
Marco Calvaruso, Gaia Pucci, Rosa Musso, Valentina Bravatà, Francesco P. Cammarata, Giorgio Russo, Giusi I. Forte, Luigi Minafra
International Journal of Molecular Sciences.2019; 20(21): 5267. CrossRef

11,779 View
266 Download
19 Web of Science
17 Crossref

Case Report

Case Report of Pulmonary Sarcoidosis Suspected to be Pulmonary Metastasis in a Patient with Breast Cancer: Hye Sook Kim, Suk-young Lee, Sang Cheul Oh, Chul Won Choi, Jun Suk Kim, Jae Hong Seo; Cancer Res Treat. 2014;46(3):317-321. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.317

Abstract PDF PubReader ePub

Standard endocrine therapy and chemotherapy can induce long-term remission in breast cancer patients; however, breast cancer can recur at any site. Pulmonary nodules with lymphadenopathy in advanced cancer patients are likely to be assumed as metastases. A 44-year-old woman with a history of breast cancer was presented to our institution with abnormal findings on 18-fluorodeoxyglucose positron emission tomography imaging, which suggested lung metastasis. She had previously been diagnosed with breast cancer (T1N2M0, Stage IIIa, intraductal carcinoma, triple negative cancer). Histological analysis of the mediastinal lymph node biopsy demonstrated sarcoidosis, showing a chronic, non-caseating, granulomatous inflammation. Our case highlights the need for non-malignant diagnoses in those with prior malignancies, and the need for histological evaluations in the event of first recurrence following potentially curative therapy.

Citations

Citations to this article as recorded by

Endobronchial ultrasound-guided transbronchial needle aspiration facilitating diagnosis of sarcoidosis in a breast cancer patient with multiple lymphadenopathy: a case report
Yuka Oride, Yumiko Koi, Tatsunari Sasada, Keiko Kajitani, Masahiro Ohara, Tomohiro Kondo, Yutaka Daimaru, Shingo Kawamura
Journal of Medical Case Reports.2022;[Epub] CrossRef
Sarcoidosis or metastatic rectal cancer? Diligent diagnosis for optimal therapeutic management
Tanya Odisho, Sonal Kaushik, An King Ang
Current Problems in Cancer: Case Reports.2022; 8: 100187. CrossRef
Pleural Schwannoma Suspected as Metastasis of Breast Cancer
Se Hyun Paek, Joohyun Woo, Kyong-Je Woo, Kwan Chang Kim, Woosung Lim
American Journal of Case Reports.2020;[Epub] CrossRef
Sarcoid-Like Lesions Mimicking Pulmonary Metastasis: A Case Series and Review of the Literature
Hendrik Eggers, Marcus Krüger, Katharina Stange, Danny Jonigk, Christian Biancosino, Thomas Rodt, Thomas Fühner, Tim Murray, Viktor Grünwald, Philipp Ivanyi
Oncology Research and Treatment.2019; 42(7-8): 382. CrossRef
Concurrent Diagnoses of Cutaneous Sarcoidosis and Recurrent Metastatic Breast Cancer: More than a Coincidental Occurrence?
Jacqueline Deen, Nick Mellick, Laura Wheller
Case Reports in Dermatological Medicine.2018; 2018: 1. CrossRef
18F-FLUOROESTRADIOL PET/CT IN DIFFERENTIAL DIAGNOSIS OF LUNG LESIONS IN BREAST CANCER PATIENTS: CASE REPORTS
N. В. Vikhrova, A. A. Odzharova, M. В. Dolgushin, D. I. Nevzorov
Siberian journal of oncology.2018; 17(5): 111. CrossRef
Coexistence of sarcoidosis and metastatic lesions: A diagnostic and therapeutic dilemma (Review)
Christoph Spiekermann, Meike Kuhlencord, Sebastian Huss, Claudia Rudack, Daniel Weiï¿½
Oncology Letters.2017;[Epub] CrossRef
Sarcoidosis Presenting with Multiple Lung Parenchymal Nodules
Hyung-Jun Kim, Jimyung Park, Jee Min Kim, Ye Jin Lee, Hye-Rin Kang, Chang-Hoon Lee
The Ewha Medical Journal.2016; 39(2): 61. CrossRef
Systemic sarcoidosis mimicking malignant metastatic disease
Irena Hammen, David Lee Sherson, Jesper Roemhild Davidsen
European Clinical Respiratory Journal.2015; 2(1): 26761. CrossRef
Baohuoside I Suppresses Invasion of Cervical and Breast Cancer Cells through the Downregulation of CXCR4 Chemokine Receptor Expression
Buyun Kim, Byoungduck Park
Biochemistry.2014; 53(48): 7562. CrossRef

18,281 View
113 Download
13 Web of Science
10 Crossref

Original Articles

A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer: Jong Gwon Choi, Jae Hong Seo, Sang Cheul Oh, Chul Won Choi, Jun Suk Kim; Cancer Res Treat. 2012;44(2):127-132. Published online June 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.2.127

Abstract PDF PubReader ePub

PURPOSE
The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer.
MATERIALS AND METHODS
Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions. The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2 of oral capecitabine twice a day on days 1-21 of a 28-day cycle.
RESULTS
Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0% (95% CI, 22.5 to 57.1%). The median time to progression and overall survival were 6.5 months (95% CI, 2.3 to 8.7 months) and 10.0 months (95% CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22%), anemia (8%), thrombocytopenia (6%), and hand-foot syndrome (10%).
CONCLUSION
Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.

Citations

Citations to this article as recorded by

Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials
Abhinav Shenoy, Amar Yousif, Muhammad Delwar Hussain
Cancers.2025; 17(8): 1319. CrossRef
Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma
Kimmen Quan, Philip Sutera, Karen Xu, Mark E. Bernard, Steven A. Burton, Rodney E. Wegner, Herbert Zeh, Nathan Bahary, Ronald Stoller, Dwight E. Heron
Practical Radiation Oncology.2018; 8(2): 95. CrossRef
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Ho Gak Kim, Myung Hwan Noh, Sang Hyub Lee, Yong-Tae Kim, Hyo Jung Kim, Chang Duck Kim, Dong Ki Lee, Kwang Bum Cho, Chang Min Cho, Jong Ho Moon, Dong Uk Kim, Dae Hwan Kang, Youn
Medicine.2017; 96(1): e5702. CrossRef
Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
P. Jiménez-Fonseca, M. P. Solis, M. Garrido, L. Faez, D. Rodriguez, A. L. Ruiz, M. L. Sanchez Lorenzo, E. Uriol, M. D. Menendez, J. M. Viéitez
Clinical and Translational Oncology.2015; 17(5): 384. CrossRef
Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
Vincent Chee Ee Phua, Wei Quan Wong, Pei Lin Tan, Anita Zarina Bustam, Marniza Saad, Adlinda Alip, Wan Zamaniah Wan Ishak
Asian Pacific Journal of Cancer Prevention.2015; 16(4): 1449. CrossRef
An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Chao Tu, Feng Zheng, Jin-Yu Wang, Yuan-Yuan Li, Ke-Qing Qian
Asian Pacific Journal of Cancer Prevention.2015; 16(14): 5681. CrossRef
Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer
Ibrahim Vedat Bayoglu, Umut Varol, Ibrahim Yildiz, Ugur Muslu, Ahmet Alacacioglu, Yuksel Kucukzeybek, Murat Akyol, Lutfiye Demir, Ahmet Dirican, Suna Cokmert, Yasar Yildiz, Bulent Karabulut, Ruchan Uslu, Mustafa Oktay Tarhan
Asian Pacific Journal of Cancer Prevention.2014; 15(17): 7119. CrossRef
Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
Jae Yun Lim, Jang Ho Cho, Se Joon Lee, Dong Ki Lee, Dong Sup Yoon, Jae Yong Cho
Cancer Research and Treatment.2014; 47(2): 266. CrossRef
Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody
PLoS ONE.2014; 9(8): e104346. CrossRef
Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance
Chunfang Xu, Airong Wu, Hua Zhu, Huaying Fang, Lele Xu, Jianxin Ye, Jiaqing Shen
Biomedicine & Pharmacotherapy.2013; 67(2): 133. CrossRef

14,902 View
67 Download
10 Crossref

Clinical Factors Related to Suspected Second Primary Lung Cancer Development in Patients with Head and Neck Cancer: Eui Bae Kim, Yong Park, Seh Jong Park, Dae Sik Kim, Jee Won Kim, Hee Yun Seo, Hwa Jung Sung, In Keun Choi, Kyong Hwa Park, Sang Cheul Oh, Chul Won Choi, Byung Soo Kim, Yeul Hong Kim, Jun Suk Kim, Sang Won Shin, Chul Yong Kim, Kwang-Yoon Jung; Cancer Res Treat. 2008;40(4):178-183. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.178

Abstract PDF PubReader ePub

Purpose

The rate of second primary lung cancer development for patients with head and neck cancer (HNC) has been noted. The aim of our study was to evaluate the incidence and clinical features of suspected second primary lung cancer that developed in patients with primary HNC.

Materials and Methods

We conducted a retrospective study of 469 patients who were newly diagnosed with HNC at the Korea University Medical Center between January 2000 and December 2006.

Results

A total of 469 patients were included (389 men and 80 women). Eighteen patients (3.8%) had suspected second primary lung cancers. Statistically significant clinical variables for lung cancer development included the origin site for the primary HNC (oro-hypopharynx and larynx) (p=0.048), abnormal chest x-ray findings (p=0.027) and the histological HNC type (squamous cell carcinoma) (p=0.032). When the second primary lung cancers were combined with HNCs, the adjusted overall survival of patients with a second primary lung cancer was 16 months (p<0.001).

Conclusions

Considering the relative risk factors for a second primary lung cancer developing in patients with HNC, advanced diagnostic tools, such as chest CT or PET CT scan, should be applied for the early detection of a second primary lung cancer.

Citations

Citations to this article as recorded by

Bridging the gap between tumor evolution and clonality diagnostics in multiple lung carcinomas
Jurriaan Janssen, Michael Allgäuer, Bauke Ylstra, Swip Draijer, Yongsoo Kim, Jan Budczies, Daniel Kazdal, Albrecht Stenzinger, Martina Kirchner, Teodora Radonic
Seminars in Cancer Biology.2026; 122: 1. CrossRef
Long-Term Survival in Metachronous Primary Malignancies: Stage III Nasopharyngeal Cancer and Stage IV Non-Small-Cell Lung Cancer
Gabriela Rahnea-Nita, Alexandru Nechifor, Mihai-Teodor Georgescu, Dorel Firescu, Adrian-Cornel Maier, Radu-Valeriu Toma, Valentin Titus Grigorean, Liliana-Florina Andronache, Roxana-Andreea Rahnea-Nita, Ionut Simion Coman, Laura-Florentina Rebegea
Journal of Clinical Medicine.2025; 14(10): 3299. CrossRef
African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer
Yusra F. Shao, Seongho Kim, John D. Cramer, Dina Farhat, Jeffrey Hotaling, Syed Naweed Raza, George Yoo, Ho‐sheng Lin, Harold Kim, Ammar Sukari, Misako Nagasaka
Head & Neck.2022; 44(10): 2069. CrossRef
Should fluorodeoxyglucose positron emission tomography/computed tomography be the first-line imaging investigation for restaging the laryngeal carcinoma patients?
Tarun Jain, Guman Singh, Sumit Goyal, Ajay Yadav, Dinesh Yadav, Nitin Khunteta, Hemant Malhotra
World Journal of Nuclear Medicine.2021; 20(02): 164. CrossRef
Modern Radiology in the Management of Head and Neck Cancer
G.J.C. Burkill, R.M. Evans, V.V. Raman, S.E.J. Connor
Clinical Oncology.2016; 28(7): 440. CrossRef
Synchronous Squamous Cell Carcinoma and Chronic Lymphocytic Leukemia of the Palate
Pablo Rosado, Soledad Fernández, Luis Junquera, Juan Carlos De Vicente
Journal of Craniofacial Surgery.2011; 22(1): 348. CrossRef

13,614 View
72 Download
6 Crossref

Pilot Study of Heptaplatin, UFT-E and Leucovorin in Advanced Gastric Carcinoma: Sang Cheul Oh, So Young Yoon, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho, Jun Suk Kim; Cancer Res Treat. 2003;35(2):117-122. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.117

Abstract PDF

PURPOSE
Heptaplatin (SKI-2053R, Sunpla ), a new platinum analogue which has a better toxicity profile than cisplatin, has been used with 5-fluorouracil (5-FU) continuous infusion for the treatment of advanced gastric carcinoma. However, continuous 5-FU infusion had a inconvenience to administration. The aim of this study was to evaluate the efficacy and toxicity of heptaplatin, UFT-E and leucovorin combination chemotherapy in advanced gastric cancer.
MATERIALS AND METHODS
A total of 22 patients was enrolled in this study at Kyung Hee University and Korea University from September 1999 to May 2001. Heptaplatin 400 mg/m2 was given as intravenous infusion for 1 hour at day 1. Oral UFT-E 360 mg/m2 and leucovorin 45 mg/day were administered for 21 consecutive days followed by a 7-day drug free interval. This schedule was repeated every 4 weeks. RESULTS: The 22 enrolled patients received 81 courses of chemotherapy and the median number of course per patient was three with a range of one to six. Five of 21 patients achieved partial responses (23.8%; 95% confidence interval, 5.6% to 42%) without complete response. Out of the 5 responding patients, three had unresectable perigastric lymph-nodes, one patient had a ovarian metastasis, and one patient had a peritoneal metastasis respectively. Main toxicities were neutropenia and nausea/vomiting. Grade 3 and 4 neutropenia were observed in 4 patients (18%) and grade 3 nausea/vomiting were observed in 5 patients (22.7%). The median time to progression was 4 months (range, 0.5 to 13 months), and median survival duration was 7.5 months (range, 2.0 to 14 months). Median response duration was 5.0 months (range, 1.5 to 10 months). CONCLUSION: A combination chemotherapy of heptaplatin, UFT-E and leucovorin has a comparable efficacy with those of previously reported heptaplatin and intravenous regimen of 5-FU and controllable toxicity in advanced gastric carcinoma. Further study with large patient population is warranted to determine the usefulness of this regimen.

Citations

Citations to this article as recorded by

Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters
Xi Hu, Fangyuan Li, Nabila Noor, Daishun Ling
Science Bulletin.2017; 62(8): 589. CrossRef
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
Dalton Transactions.2010; 39(35): 8113. CrossRef
A Phase II Trial of Haptaplatin/5-FU and Leucovorin for Advanced Stomach Cancer
Won Sup Lee, Gyeong-Won Lee, Hwal Woong Kim, Ok-Jae Lee, Young-Joon Lee, Gyung Hyuck Ko, Jong-Seok Lee, Joung Soon Jang, Woo Song Ha
Cancer Research and Treatment.2005; 37(4): 208. CrossRef
Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study
Myung-Ju Ahn, Ho-Suck Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Oh Young Lee, Ho-Soon Choi, Sung-Joon Kwon
Cancer Research and Treatment.2004; 36(3): 182. CrossRef

5,723 View
23 Download
4 Crossref

Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer: Seok Jin Kim, Hwa Jung Sung, Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Kwang Taek Kim, Young Ho Choi, Jun Suk Kim; Cancer Res Treat. 2002;34(6):421-425. Published online December 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.6.421

Abstract PDF: PURPOSE
The combination of cisplatin and etoposide has been a common first line regimen for the treatment of small cell lung cancer (SCLC). The schedule dependence, and equal efficacy, of the oral and intravenous dosing of etoposide has led to prolonged administration of oral etoposide, which is known to produce an encouraging response in SCLC. To improve the efficacy of the cisplatin/etoposide combination, we administered oral etoposide, with added ifosfamide, which had significant single agent activity against SCLC. We conducted this study to evaluate the efficacy and toxicity of the cisplatin, ifosfamide and oral etoposide (PIE) combination in patients with extensive small cell lung cancer.
MATERIALS AND METHODS
Twenty-five patients with histologically confirmed extensive small cell lung cancer were enrolled into this study between January 2000 and May 2002. They were treated with, cisplatin at 20 mg/ m2/day, ifosfamide 1.5 g/m2/day, with mesna (all given intravenously on Days 1~3), and oral etoposide 50 mg/m2 on days 4~17. This cycle was repeated every 4 weeks for up to 6 cycles. We evaluated the corresponding disease responses and toxicities.
RESULTS
The patients' characteristics were as follows: median age 65 years (32~75), 19 males and 6 females. The performance stati were ECOG 0 in 3 patients, ECOG 1 in 12 and ECOG 2 in 10. Sixteen patients had a partial response, 2 had a stable disease and 4 had a progressive disease. Thus, the overall objective response rate was 72.7% (95% CI: 49.6~88.4%), with a median response duration of 7 months (95% CI: 3.5~10.5 months). Myelosuppression was the major observed toxicity. Grades III and IV neutropenia were observed in 42 (46.1%) of the 91 cycles. Significant non-hematological toxicities (>or=Grade III) were uncommon, with the exception of nausea and vomiting.
CONCLUSION
The response rate to the combination of cisplatin, ifosfamide and oral etoposide was similar to that of other combination chemotherapy studies in patients with extensive disease small cell lung cancer. The toxicity of the regimen was considered acceptable.

5,451 View
26 Download

Pirarubicin, UFT, Leucovorin Chemotherapy in Non-embolizable and Transcatheter Arterial Chemoembolization-Failed Hepatocellular Carcinoma Patients; A Phase II Clinical Study: Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Jong Eun Yeon, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Kwan Soo Byun, Jun Suk Kim, Chang Hong Lee; Cancer Res Treat. 2002;34(4):280-283. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.280

Abstract PDF: Hepatocellular carcinomas are one of the most common malignancies in the world. However, no effective therapeutic modality has been proven to prolong the survival of patients in an inoperable stage. The purpose of this study was to determine the response rate and the toxicities of a combination of pirarubicin, UFT and leucovorin in patients with non-embolizable hepatocellular carcinomas, or who had progressed during their transcatheter arterial chemoembolization treatment.
MATERIALS AND METHODS
Of 23 patients with a hepatocellular carcinoma, 11 had progressed during a transcatheter arterial chemoembolization, with the other 12 being transcatheter arterial chemoembolization-naive. All the patients were treated with pirarubicin (70 mg/m2 i.v., day 1), UFT (350 mg/m2 P.O., day 1~21), and leucovorin (25 mg/m2 P.O., day 1~21).
RESULTS
Twenty patients were able to be evaluated, with a partial response being achieved in four, giving an overall response rate of 20% (95% confidence interval, 7~44%). The median overall survival time was 6 months, and the median survival time of the transcatheter arterial chemoembolization-naive patients was significantly longer than that of those treated by transcatheter arterial chemoembolization (p=0.012). The most significant dose-limiting toxicity was leucopenia and thrombocytopenia.
CONCLUSION
The combination of pirarubicin, UFT and leucovorin therapies showed marginal antitumor activity and significant toxicity in patients with non-embolizable or failed transcatheter arterial chemoembolization hepatocellular carcinomas.

5,121 View
17 Download

Randomized Controlled Open Labelled, Phase III Trials, Comparing the Efficacy between Fentas(R) and Durogesic(R) Patches in Controlling Cancer Pain: Multicenter Trial: Myung Ju Ahn, Tae June Jung, Jung Hye Choi, Mi Ran Oh, Hwi Joong Yoon, Jun Suk Kim, Chul Won Choi, Kyung Wook Hur, Dae Sik Hong, Hee Sook Park, Sung Kyu Park, Jung Ae Lee, Young Suk Park, Hyonggi Jung; Cancer Res Treat. 2002;34(3):165-169. Published online June 30, 2002; DOI: https://doi.org/10.4143/crt.2002.34.3.165

Abstract PDF: PURPOSE
Fentanyl is a synthetic opioid and transdermal therapeutic system (TTS), designed to release the drug into the skin at a constant rate, ranging from 25 to 100 microgram/hr, for up to 3 days. For the control of chronic cancer pain, Durogesic(R) patches (Janssen Co., USA) are now widely used. Recently, the Hana Company in Korea developed a new fentanyl patch, Fentas(R) using a different method. To compare the efficacy, and safety, of the fentanyl patch manufactured in Korea (Hana Pharm. Co. Ltd), with the Durogesic(R) patch, in controlling cancer pain, we performed randomized controlled, open labelled, phase III studies. MATERIALS AND METGODS: From January 2000 to April 2001, 85 patients were enrolled, 69 of whom (42 in D arm and 43 in F arm) completed the study, and were therefore assessable for per protocol (PP) analyses.
RESULTS
There were no significant differences between the two groups in baseline characteristics, with the exception of age. The primary end point was to show the therapeutic equivalence of the two patches. In these clinical trials, the confidence interval of difference, between the test drug (Fentas(R)) and the control (Durogesic(R)), was 0.027~ +0.124 by intention to treat (ITT) analysis. Even if the upper confidence interval exceeds + 0.1, the test drug is not superior to the control drug, because the confidence interval includes 0. However, by PP analysis, the confidence interval lies exactly within +/- 0.1. Therefore, we could conclude the two patches are therapeutically equivalent. The second endpoint was the difference of visual analog scale (VAS) between the baseline and the average of three measurements after treatment. The difference in VAS was 50.44+/-10.28 for the F arm, and 44.69+/-11.00 for the D arm. By PP analysis the test drug was superior to the control (p=0.028). The rescue morphine amount was 81.21+/-124.76 for F arm and 66.19+/-115.9 for D arm, and there was no significant difference between the two groups (p=0.6063). The most common adverse effects of both fentanyl patches were nausea or vomiting (55.3%), somnolence (50.0%), constipation (39.5%), gastrointestinal discomfort (57.9%) and headaches (25.0%). In general there was no significant difference in side effects or laboratory data between the two groups.
CONCLUSION
These findings suggest that Fentas(R) patches, administered every 3 days, are effective, safe, and well tolerated for the treatment of most patients with cancer pain and is as effective or better than Durogesic(R).

5,350 View
43 Download

Phase II Trial of Gemcitabine, UFT-E, Leucovorin Combination Chemotherapy in Advanced Pancreatic Adenocarcinoma: So Young Yoon, Kyong Hwa Park, Sang Chul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Jae Seon Kim, Chang Duck Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2002;34(2):111-116. Published online April 30, 2002; DOI: https://doi.org/10.4143/crt.2002.34.2.111

Abstract PDF

PURPOSE
To evaluate the efficacy and toxicity of a Gemcitabine, UFT-E, Leucovorin combination chemotherapy in the treatment of advanced pancreatic adenocarcinoma. PATIENTS AND METHODS: Patients <=70 years, with no prior chemotherapy and with bidimensionally measurable advanced pancreatic adenocarcinoma, ECOG performance status <=2, and adequate bone marrow, kidney, and liver function were eligible for this trial. Eligibility criteria for clinical benefit assessment were pain with at least a daily analgesic consumption of two nonsteroidal anti-inflammatory drugs or a Karnofsky performance status between 50 and 70. Treatment consisted of 1,000 mg/m2 of Gemcitabine on days 1, 8 and 15, repeated every 4 weeks, with UFT-E administered orally 500 mg-700 mg by body surface area (BSA). Leucovorin was administered 45 mg/day orally. Dosages of UFT-E and Leucovorin were divided and administered three times per day from day 1 to day 21. After 7 days of rest, UFT-E and Leucovorin were administered repeatedly.
RESULTS
Twenty-three patients were enrolled between April 1999 to April 2000. Eighty two cycles (median, four cycles) were delivered to all patients. The objective response rate was 15.8% in 19 assessable patients and 13.0% in the intent-to-treat population. Twelve patients (57.9%) displayed stable disease. Grade 3 or 4 neutropenia occurred in 30.4% of patients, nausea/vomiting in 8.3%, diarrhea in 4.3%, and mucositis in 4.3%. The median time to progression was 8 months. The median survival was 8 months in the assessable population and 6 months in the intent-to-treat population Clinical benefit was achieved in 11 (57.9%) of 19 assessable patients.
CONCLUSION
Gemcitabine, UFT-E, Leucovorin combination chemotherapy is a well-tolerated and safe regimen in cases of advanced pancreatic adenocarcinoma. Although the response rate is low, it shows a survival benefit and clinical benefit and deserves further evaluation in a phase III trial.

Citations

Citations to this article as recorded by

Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim, Myung Ah Lee, Seock Ah Im, Heung Moon Chang, Jae Yong Cho, Dae Young Zang, Bong Seog Kim, Jun Suk Kim
Cancer Chemotherapy and Pharmacology.2009; 64(2): 317. CrossRef

5,815 View
21 Download
1 Crossref

Clinical Significance of Peripheral Blood CEA mRNA Expression in Gastric Cancer Patients Underwent Curative Resection: Jae Hong Seo, Sun Hee Park, Chang Won Bak, Chul Won Choi, Byoung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Young Jae Mok, Jong Suk Kim, Seon Ae Han, Jung In Yoon; Cancer Res Treat. 2001;33(6):483-488. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.483

Abstract PDF: PURPOSE
Recent advances in molecular technology have made it possible to detect small numbers of circulating tumor cells in the peripheral blood or bone marrow. Carcinoembryonic antigen (CEA) is an oncofetal antigen that is expressed in epithelial tumor cells. CEA mRNA may be a reliable marker for the detection of tumor cells in the peripheral blood of patients with epithelial cancer.
MATERIALS AND METHODS
We analyzed the peripheral blood of 46 patients with gastric cancer who had undergone curative resection. The presence of CEA mRNA was serially monitored using RT-PCR (Preop, Post op 15 day, 2 months (m), 4 m, 6 m, 8 m, 10 m, 12 m). The clinical characteristics, serum CEA level and immunohistochemical staining of tumor tissue were also evaluated. Patients were followed up for 6 to 12 months.
RESULTS
There was no significant relationship seen between CEA mRNA RT-PCR positivity in the peripheral blood and sex, stage, serum CEA level or immunohistochemical staining for CEA antigen, During follow up,eight patients experienced recurrence; were positve for CEA mRNA RT-PCR recurrence was seen in 66.7% (6/9) of the patients who before clinical recurrence as compared to 5.4% (2/37) of patients who were negative (p=0.0002). Serial changes of CEA mRNA RT-PCR correlated with clinical recurrence; 100% in the positively converted group (3/3), 0% in the negatively converted group(0/18), 50% in all positive group (3/6) and 10.5% in all negative group (2/19) experienced recurrence, respectively.
CONCLUSION
RT-PCR analysis of CEA mRNA in the peripheral blood seems to be a promising tool for the early detection of micrometastatic circulating tumor cells in gastric cancer patients and may be useful in determining patients at high risk for recurrence. However, definitive correlation with recurrence certainly requires a longer follow up duration in further studies.

5,617 View
19 Download

Retinoic Acid as a Radiosensitizer on the Head and Neck Squamous Cell Carcinoma Cell Lines: Jae Hong Seo, Kap No Lee, Sun Hee Park, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2001;33(4):335-342. Published online August 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.4.335

Abstract PDF

PURPOSE
Retinoic acid is a substance that has previously been reported to increase radiosensitivity, but at concentrations likely to inhibit cell growth or to induce celluar differentiation. We choose head and neck cancer cell lines to investigate the role of retinoic acid as a radiosensitizer and to elucidate the mechanism through the changes in the expression of retinoid receptors and squamous cell differentiation marker.
MATERIALS AND METHODS
Three cell lines (PCI-50, SqCC/ Y1 and UMSCC-11B) were used. 7-AAD staining for apoptosis and Western blot analysis for RAR-alpha, beta, gamma, RXR-alpha, beta, gamma and involucrin were performed after various treatments (control, beta-all-trans-retinoic acid (t-RA) only (10 6 M), radiation only (3 Gy), radiation with t-RA).
RESULTS
The synergistic radiosensitivity effect of t-RA was seen only radioresistant UMSCC-11B cell line. Expression of RAR-beta was induced by t-RA in maily UMSCC- 11B cell line. RAR-alpha,gamma, and RXR-alpha, beta, gamma expression were not changed in all cell lines tested. Expression of involucrin was inhibited by t-RA in PCI-50 cell line but other two cell lines were not changed by t-RA treatment.
CONCLUSION
We found that only radioresistant cell line (UMSCC-11B) showed synergistic radiosensitivity effect by t-RA and this mechanism may be through RAR-beta expression induction.

Citations

Citations to this article as recorded by

Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity
Xiaochen Meng, Xiaoqian Li, Yi Gao, Shuyu Zhang
Molecular Cancer.2025;[Epub] CrossRef
Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway
Lingyun Qiu, Yan Ma, Xiaohua Chen, Liheng Zhou, Haibo Zhang, Guansheng Zhong, Lei Zhang, Jianming Tang
Journal of Translational Medicine.2021;[Epub] CrossRef
CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells
Hang Li, Jun Che, Mian Jiang, Ming Cui, Guoxing Feng, Jiali Dong, Shuqin Zhang, Lu Lu, Weili Liu, Saijun Fan
Cell Communication and Signaling.2020;[Epub] CrossRef
Detection of RTP801, a Gene That is Differentially Expressed in Irradiated HeLa Cells
Young-Sook Lee, Moon-June Cho, Jeung Hoon Lee, Woong-Hee Lee, Jun-Sang Kim
Cancer Research and Treatment.2004; 36(4): 263. CrossRef

5,565 View
24 Download
4 Crossref

Effects of REtinoic Acid and Radiation on the Growth of Cell Lines of Human Head and Neck Squamous Cell Carcinoma: Jae Hong Seo, Young Ah Yoo, In Keun Choi, Seok Jin Kim, Chul Won Choi, Byung Soo Kim, Chul Yong Kim, Sang Won Shin, Yeol Hong Kim, Myung Sun Choi, Joon Seok Kim; J Korean Cancer Assoc. 1998;30(4):772-780.

Abstract PDF: PURPOSE
Mammalian tumor cells differ in their response to ionizing radiation to a degree that some patients are readily curable with conventional doses of radiation, while others are rarely controlled. In experimental systems, it is possible to demonstrate differences between cell lines both in intrinsic radiosensitivity and in the apparent capacity to repair damage. Retinoic acid is a substance that has previously been reported to increase radiosensitivity, but at concentrations likely to have cytostatic effects or induce cellular differentiation. We chose several head and neck cancer cell lines to investigate radiation sensitivity and synergism in combination with retinoic acid. Material and Methods: Seventeen head and neck cancer cell lines (MDA886, P1, P13, A-431, PCI-50, UMSCC-10A, UMSCC-10B, UMSCC-11A, UMSCC-11B, UMSCC-17A, UMSCC-17B, UMSCC-19, UMSCC-22B, UMSCC-30, UMSCC-38, 1YA, 1YB) are irradiated with variable dose of radiation (1 Gy, 5 Gy, 9 Gy) for determination of radiosensitivity of each cell lines. The less radiosensitive cell lines are treated with retinoic acid for evaluation of the effects of retinoic acid on cellular X-ray sensitivity and recovery from X ray-induced potentially lethal damage.
RESULTS
Lowest growth inhibition rates are seen UMSCC-11A and 1YA cell lines in 1 Gy, so that we treated with retinoic acid such cell lines. We obtained the following RESULTS: 1) two cell lines appear not inhibitory effect on recovery from X-ray induced potentially lethal damage but growth inhibition synergism when irradiated with retinoic acid in 1 Gy of radiation dose. 2) two cell lines were little effect on radiosensitivity and inhibitory effect on recovery from X-ray damage in 0.5 Gy radiation dose.
CONCLUSION
We found that direct radiosensitizing effects of retinoic acid on 1 Gy of radiation dose may act synergistically for cell growth inhibition in vitro study(three cell lines: UMSCC-11A, 1YA, UMSCC-11B). Further in vitro and in vivo experiments are now necessary to evaluate retinoic acid as radiosensitizer for head and neck cancer radiation therapy.

4,114 View
24 Download

Effect of ondansetron in prevention of nausea and vomiting associated with cisplatin chemothrapy in cancer patients: Sang Won Shin, Kyung Mook Choi, Jong Eun Yun, Sang Myun Park, Chul Won Choi, Joon Suk Kim; J Korean Cancer Assoc. 1993;25(2):299-306.

Abstract PDF: No abstract available.

3,115 View
14 Download

The Effects of Granulocyte Colony Stimulating Factor on Neutropenia Induced by the Chemotherapy in the Solid Tumor Patient: Sang Won Shin, Young Jin Nam, Chul Won Choi, Gwan Gyu Song, Jun Suk Kim, Soon Duck Kim, Yeul Hong Kim; J Korean Cancer Assoc. 1994;26(1):144-151.

Abstract PDF: We evaluated the effect of aranulocyte colony stimulating factor (G-CSF) to prevent chemo- therapy induced neutropenia and fever development during neutropenic period. The twenty patients with solid tumor were treated with various cytotoxic chemotherapeutic agents at least two cycles. The patients were given G-CSF 75pg/day after 2nd cycle chemotherapy for least 14 consecutive days and clinical, laboratory results were compared to the first cycle's results. Treatment with G-CSF resulted in increase of mean neutrophil count(320+-230/mm(3) vs 1030 +-1020/mm(2)), reduced the duration of neutropenic days(4.25 dyas vs 1.30 days, absolute neutrophil count less than 500/mm) snd reduced the incidence of neutropenic fever(75% vs 25% ). The side effect af G-CSF was not so significant. These results demonsrated that the use of G-CSF as an adjunct to chemotherapy with various solid cancer patients was well tolerated and led to reduction in the incidence of neutropenic fever; in the terms of incidence, duratian, and severity of neutropenia.

3,516 View
18 Download

The Mechanism of Retinoic Acid-induced Growth Suppression in Head and Neck Squamous Cancer Cell Lines: Seok Jin Kim, Chang Won Paek, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Aree Kim, Kap No Lee, Sun Han Kim, Geon Choi, Young A Yoo; J Korean Cancer Assoc. 2000;32(4):783-792.

Abstract PDF: PURPOSE
Retinonic acid (RA) has been reported to induce differentiation and growth inhibition in various head and neck squamous cancer cell (HNSCC) lines. We hypothesized that this growth inhi bition might be explained by RA-induced apoptosis on cell cycle arrest mechanism. Therefore, we studied the degree of RA-induced apoptosis with variable RA concentration and exposure duration. MATERIAL AND METHODS: The flow cytometric evaluation of apoptosis degree and cell cycles were carried out with 7-amino actinomycin D (7AAD) and propium iodide (PI) respectively, with var ious RA exposure durations (2, 3, 6 day) and concentrations (conrol, 10 6, 10 7, 10 8, 10 9, 10 10 mole). Two different HNSCC lines (1483, SqCC/Y1) were used and the experiment was repeated twice.
RESULTS
The maximal fraction of apoptosis in 1483 and SqCC/Y1 cell lines were observed at same concentration and exposure duration (1483: 6th day & 10 6, mole, and SqCC/Y1: 6th day & 10 6 mole). In our experimental model, RA did not induce specific cell cycle arrest in these HNSCC lines. However we observed S phase fraction increase in SqCC/Y1 cell line after RA treatment.
CONCLUSION
We suppossed that in HNSCC lines, RA-induced cell growth inhibition could be explained by not only RA-induced apoptosis but also cell cycle arrest. Futher, in vitro study has been carried out to elucidate the RA-iduced cell growth inhibition mechanism in our laboratory.

3,599 View
19 Download

Concurrent Chemoradiation Therapy with Cisplatin and Oral Etoposide for Locally Advanced Non-small Cell Lung Cancer: Chang Won Paek, So Young Yoon, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jae Jung Shim, Kyung Ho Kang, Jun Suk Kim, Chul Yong Kim, Myung Sun Choi, Young Ho Choi, Kwang Tak Kim; J Korean Cancer Assoc. 2000;32(4):682-689.

Abstract PDF: PURPOSE
Prognosis of locally advanced inoperable non-small cell lung cancer (NSCLC) treated with radiation therapy alone has been disappointing. In recent years, concurrent chemoradiation therapy has potential of improving both local and metastatic disease-free survival. This phase II study was undertaken to determine the feasibility, toxicity, response rate, local control rate, and survival duration of locally advanced NSCL patients treated with concurrent chemoradiation using cisplatin and oral etoposide. MATERIAL AND METHODS: Forty-seven patients were enrolled and forty-one patients were evaluable. Chemotheray consisted of cisplatin 50 mg/m2/IV on days 1 and 8 and oral etoposide 100 mg/day on days 1 to 5 and 8 to 12 which was repeated, every 4 weeks for two cycles during radiation therapy. Radiation therapy was administered to a total dose of 6300 cGY.
RESULTS
Among 41 evaluable patients, six patients achieved complete response, and twenty had partial response, for an overall response rate of 63.4% (95% confidence interval; 48.4% to 75.4%). Stable disease was reported in 10 patients (24.4%) and another 5 (12.2%) showed disease pro gression. Overall survival rate was 76% at 1 year, 34% at 2 years. Median survival duration was 17 months (range; 3 to 41 ). Eighty-three percents of patients had radiation pneumonitis but only one patients needed medical treatment.
CONCLUSION
Concurrent chemoradiation therapy with cisplatin and oral etoposide at this level is a well tolerated and feasible.

4,021 View
22 Download

Amplification of the c-erbB-2 Prto - Oncogene in Primary Human Gastric Cancers: Chul Won Choi, Jae Hong Seo, Byung Soo Kim, Sang Won Shin, Jun Suk Kim, Young Jae Mok, Jong Suk Kim, Bum Hwan Koo; J Korean Cancer Assoc. 1995;27(2):195-202.

Abstract PDF: The c-er6B-2 proto-oncogene has been found to be amplified in many human tumors induding breast, stomach, kidney and lung cancers. In order to evaluate the amplification status of c-erbB-2 proto-oncogene in stomach cancer which is the most common cancer in Korea, fortyfive sets of specimens including tumor tissue and normal stomach tissue(5 cm at least away from primary tumor, histologically normal)were measured by Southern hybridization technique. Ten micrograms of EcoRI-digested DNA was electrophoresed in an 0.8% agarose gel and transferred to a nylon memebrane and hybridized with a c-erbB-2 probe, washed under stringent conditions and autoradiographed against Hyperfilm with intenaifying screens at 70`C, for 3 days. In the results. two of the 45 gastric carcinomas(4.4%) were amplified 2-to-4-fold. Thus, the amplified c-erbB-2 gene may have a role in the evolution of gastric carcinoma, as dose in some carcinoma.

3,305 View
13 Download

First
Prev
Page of 1
Next
Last

Search